Without a doubt, 2020 has been overwhelming for many reasons.  Perhaps lost among the bigger news cycles of #COVID19, the presidential race, and now the Supreme Court, has been the staggering progress that has been made in #LungCancer through the year.  There has been a remarkable run of FDA approvals, including drugs for non-small cell lung cancer (NSCLC) with RET rearrangements and MET exon 14 mutations, new first line therapies for NSCLC with EGFR mutations and ALK rearrangements, and new first line immunotherapy options for a variety of lung cancer scenarios.  This progress continued at the European Society of Medical Oncology’s virtual meeting (#ESMO20) at the end of September.  There was certainly a lot of buzz on #Twitter.  As indicated by this poll, lung cancer was arguably the hottest topic of cancer discussion at #ESMO20.  https://twitter.com/TargetedOnc/status/1308032846129442816

The lung cancer abstracts covered a variety of topics.  It is therefore worth reflecting upon several of the presentations from #ESMO20 and upon how they fit into the bigger picture of lung cancer care.  Our community is clearly benefiting from better drugs, better targeted to individual patients.  Critically, as alluded to in August by @NEJM, this is leading to better survival of our patients (https://www.nejm.org/doi/full/10.1056/NEJMoa1916623).

With that remarkable progress in mind, please join moderator Dr. Brendon Stiles (@BrendonStilesMD) for #LCSM Chat on Thursday, October 1st, at 8 pm Eastern Time (5 pm Pacific) to discuss the following hot topics:

• T1.  What is happening with KRAS?
• T2.  Are there any new targets or new drugs that are compelling?
• T3.  Are these drugs leading to longer survival?  To cures?
• T4.  What is happening in earlier stage lung cancer?
• T5.  How are virtual conferences working out and how can patients/advocates participate?

Please join us, and bring your experiences and wisdom!  Remember to include #LCSM in ALL your tweets so the other chat participants can see them. You can read a primer on participating in the chat here.